Osimertinib significantly prolonged OS compared with previous standard-of-care first-line therapies for patients with locally advanced or metastatic, EGFR-mutated non-small cell lung cancer, according to the agent’s manufacturer.

Osimertinib (Tagrisso, AstraZeneca) — a third-generation, irreversible EGFR tyrosine kinase inhibitor — is already approved in the United States for first-line treatment of EGFR-mutated metastatic NSCLC. It is the only therapy to confer a significant OS benefit in this setting.